Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart
failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is often assumed to be associated
with wild‐type TTR genotype (ATTRwt) in elderly patients (aged≥ 70), some of whom are …

Aims The incidence and risk factors of pacemaker (PM) implantation in patients with cardiac
amyloidosis (CA) are largely unexplored. We sought to characterize the trends in the …

Aim Epidemiology of wild‐type transthyretin cardiac amyloidosis (ATTRwt‐CA) remains
poorly defined. A better characterization of pathways leading to ATTRwt‐CA diagnosis is of …

Cardiac amyloidosis (CA) is an underdiagnosed condition caused by the deposition of
misfolded proteins, namely immunoglobulin light chains and transthyretin, in the …

Aims To investigate the prognostic value of the right ventricle-to-pulmonary artery (RV-PA)
coupling in patients with either transthyretin (ATTR) or immunoglobulin light-chain (AL) …

The epidemiology of cardiac amyloidosis (CA), traditionally considered a rare and incurable
disease, has changed drastically over the last ten years, particularly due to the advances in …

Cardiovascular diseases (CVDs) are classed as diseases of aging, which are associated
with an increased prevalence of atherosclerotic lesion formation caused by such diseases …

Radionuclide bone scintigraphy is the cornerstone of an imaging-based algorithm for
accurate non-invasive diagnosis of transthyretin cardiac amyloidosis (ATTR-CA). 1 In …